09:27 AM EDT, 10/06/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that Botox, also referred to as onabotulinumtoxinA, met the primary endpoint in a phase 2 trial evaluating the injection as a treatment for upper limb essential tremor, a neurological condition.

The company said that compared with placebo, onabotulinumtoxinA displayed "statistically significant" improvements in the Tremor Disability Scale-Revised score at week 18. Abbvie ( ABBV ) also said that the trial met all six secondary endpoints.

The company noted that muscular weakness was the most common adverse event observed in the trial, with reported rates of 24.5% in the group that was given onabotulinumtoxinA, compared with 2.3% in the placebo group. The company, said, however, that these instances were localized and transient, with most classified as mild or moderate in nature.